Shares of GlaxoSmithKline plc (NYSE:GSK) have earned an average rating of “Buy” from the twenty brokerages that are currently covering the firm. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $45.67.

A number of research analysts have weighed in on the company. TheStreet raised GlaxoSmithKline plc from a “c” rating to a “b” rating in a report on Friday. Zacks Investment Research downgraded GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a report on Wednesday, March 29th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline plc in a report on Wednesday, April 5th. BNP Paribas raised GlaxoSmithKline plc from an “underperform” rating to a “neutral” rating and lowered their target price for the company from $45.58 to $37.20 in a report on Wednesday, April 5th. Finally, Exane BNP Paribas raised GlaxoSmithKline plc from an “underperform” rating to a “neutral” rating in a report on Wednesday, April 5th.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Given Consensus Recommendation of “Hold” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/23/glaxosmithkline-plc-gsk-given-consensus-recommendation-of-hold-by-analysts.html.

A number of institutional investors have recently added to or reduced their stakes in GSK. Bronfman E.L. Rothschild L.P. boosted its position in GlaxoSmithKline plc by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in GlaxoSmithKline plc by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 2,359 shares in the last quarter. Physicians Financial Services Inc. boosted its position in GlaxoSmithKline plc by 25.9% in the third quarter. Physicians Financial Services Inc. now owns 2,691 shares of the pharmaceutical company’s stock valued at $116,000 after buying an additional 553 shares in the last quarter. Heritage Trust Co purchased a new position in GlaxoSmithKline plc during the first quarter valued at $123,000. Finally, Westwood Holdings Group Inc. boosted its position in GlaxoSmithKline plc by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock valued at $124,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 8.41% of the company’s stock.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.79% during midday trading on Tuesday, reaching $42.96. The company had a trading volume of 3,320,118 shares. GlaxoSmithKline plc has a 12-month low of $37.20 and a 12-month high of $45.58. The firm has a market capitalization of $104.95 billion, a price-to-earnings ratio of 49.04 and a beta of 0.94. The company has a 50 day moving average of $41.86 and a 200 day moving average of $40.27.

GlaxoSmithKline plc (NYSE:GSK) last posted its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.62. GlaxoSmithKline plc had a return on equity of 100.68% and a net margin of 3.11%. The company had revenue of $9.23 billion for the quarter, compared to the consensus estimate of $9.09 billion. Analysts anticipate that GlaxoSmithKline plc will post $2.82 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 13th. Shareholders of record on Friday, May 12th will be issued a dividend of $0.483 per share. This represents a $1.93 annualized dividend and a yield of 4.50%. The ex-dividend date of this dividend is Wednesday, May 10th. This is a boost from GlaxoSmithKline plc’s previous quarterly dividend of $0.46. GlaxoSmithKline plc’s dividend payout ratio (DPR) is currently 389.36%.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

12 Month Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.